Holen Sie sich die Stockscreener-App
320.18
0.39%
0.915
Schlusskurs vom Vortag:
$319.26
Offen:
$319.35
24-Stunden-Volumen:
29,778
Relative Volume:
0.09
Marktkapitalisierung:
$12.61B
Einnahmen:
$1.45B
Nettoeinkommen (Verlust:
$171.05M
KGV:
73.67
EPS:
4.3459
Netto-Cashflow:
$212.73M
1W Leistung:
-0.71%
1M Leistung:
-1.28%
6M Leistung:
-5.62%
1J Leistung:
+11.64%
1-Tages-Spanne:
$319.21
$320.90
1-Wochen-Bereich:
$319.18
$323.70
52-Wochen-Spanne:
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
Firmenname
Penumbra Inc
Sektor
Branche
Telefon
(510) 995-2486
Adresse
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
320.12 | 12.58B | 1.45B | 171.05M | 212.73M | 4.3459 |
ABT
Abbott Laboratories
|
106.16 | 182.59B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.88 | 118.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
273.60 | 106.03B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.62 | 65.19B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.54 | 49.99B | 6.30B | 1.07B | 1.09B | 1.8406 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-11-18 | Eingeleitet | Wells Fargo | Underweight |
| 2025-10-08 | Hochstufung | Needham | Hold → Buy |
| 2025-09-02 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-14 | Eingeleitet | BofA Securities | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-12-11 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | Eingeleitet | Stifel | Buy |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-31 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-07-31 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-29 | Herabstufung | Needham | Buy → Hold |
| 2023-01-30 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-10-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-09-09 | Hochstufung | Needham | Hold → Buy |
| 2022-07-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-04-19 | Eingeleitet | Deutsche Bank | Buy |
| 2022-03-08 | Eingeleitet | Needham | Hold |
| 2021-09-16 | Eingeleitet | Truist | Buy |
| 2021-06-04 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-12-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-10-07 | Fortgesetzt | Canaccord Genuity | Buy |
| 2020-09-29 | Eingeleitet | BTIG Research | Buy |
| 2020-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-05-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-05-21 | Eingeleitet | William Blair | Outperform |
| 2018-10-29 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-10-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-02-21 | Eingeleitet | William Blair | Outperform |
| 2018-01-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-11-30 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-13 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Penumbra Inc Aktie (PEN) Neueste Nachrichten
Price to earnings forward of Penumbra, Inc. – NYSE:PEN - TradingView
Penumbra, Inc. (PEN): Growth Potential Amidst Analyst Consensus And Market Dynamics - DirectorsTalk Interviews
Discipline and Rules-Based Execution in PEN Response - Stock Traders Daily
BSP:P2NB34 Enterprise Value: R$-100 Mil | Fairly Valued - GuruFocus
BSP:P2NB34 Shareholder Yield %: 0.05% | Fairly Valued - GuruFocus
BSP:P2NB34 Revenue: R$7,963 Mil | Fairly Valued - GuruFocus
Penumbra Stock Price Forecast. Should You Buy PEN? - StockInvest.us
BSP:P2NB34 GF Value: R$57.41 | Fairly Valued - GuruFocus
BSP:P2NB34 ROCE %: 10.74% | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) Loans Receivable : R$0 Mil (As of Jun. 2026) - GuruFocus
BSP:P2NB34 3-Year EPS without NRI Growth Rate: 188.40% — 5 - GuruFocus
Penumbra (BSP:P2NB34) Land And Improvements : R$0 Mil (As of Jun. 2026) - GuruFocus
Q3 2025 Penumbra Inc Earnings Call Transcript - GuruFocus
BSP:P2NB34 Other Current Assets: R$268 Mil | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) Total Long-Term Assets : R$3,231 Mil (As of Jun. 2026) - GuruFocus
BSP:P2NB34 Net Income: R$853 Mil | Fairly Valued - GuruFocus
BSP:P2NB34 FCF Yield %: 1.79 — 2457% Above Median - GuruFocus
BSP:P2NB34 Market Cap: R$2,172 Mil | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) 12-1 Month Momentum % : N/A% (As of Sep. 05, 2026) - GuruFocus
BSP:P2NB34 3-Year RORE %: 46.88 | Fairly Valued - GuruFocus
BSP:P2NB34 PE Ratio (TTM): 2.55 — 99% Below Median - GuruFocus
Penumbra (BSP:P2NB34) 3-1 Month Momentum % : N/A% (As of Sep. 04, 2026) - GuruFocus
BSP:P2NB34 Net-Net Working Capital: R$75.32 | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) Other Income (Minority Interest) : R$0 Mil (TTM As of Jun. 2026) - GuruFocus
Penumbra (BSP:P2NB34) Repurchase of Stock : R$0 Mil (TTM As of Jun. 2026) - GuruFocus
BSP:P2NB34 Forward PE Ratio: 1.72 | Fairly Valued - GuruFocus
Penumbra Inc Stock Operating Data - GuruFocus
BSP:P2NB34 Pre-Tax Income: R$1,082 Mil | Fairly Valued - GuruFocus
Penumbra, Inc. (PEN) Stock Analysis: Unraveling The 12.48% Potential Upside - DirectorsTalk Interviews
Incuvate Files Patent Infringement Lawsuit Against Penumbra - The Manila Times
Trillium Asset Management LLC Acquires New Stake in Penumbra, Inc. $PEN - MarketBeat
BlackRock Inc. Invests $1.36 Billion in Penumbra, Inc. $PEN - MarketBeat
Incuvate Says Penumbra Infringed Blood Clot Detection System (1) - Bloomberg Law News
Penumbra, Inc. (NYSE:PEN) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Penumbra (NYSE: PEN) grants president 3,060 RSUs with multi-year vesting - Stock Titan
Penumbra (PEN) Results at a Glance: Reported EPS Misses Expectations for This Review; Trading-Day Reaction: The Share Price Sheds 0.74% in the Available RecordForward Guidance Trends - vinanet.vn
NINE MASTS CAPITAL Ltd Acquires New Position in Penumbra, Inc. $PEN - MarketBeat
Citizens Financial Group Inc. RI Invests $9.88 Million in Penumbra, Inc. $PEN - MarketBeat
Penumbra, Inc. (PEN) Stock Analysis: Exploring a 10.65% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Fidelity Advisor Mid Cap II Fund's Penumbra Inc(PEN) Holding History - GuruFocus
Alberta Investment Management Corp Invests $10.46 Million in Penumbra, Inc. $PEN - MarketBeat
Neurothrombectomy Devices Market Size, Share | Growth [2034] - Fortune Business Insights
S&CO Inc. Takes Position in Penumbra, Inc. $PEN - MarketBeat
Technical Reactions to PEN Trends in Macro Strategies - Stock Traders Daily
Penumbra, Inc.: Financial Data Forecasts Estimates and Expectations | PEN | US70975L1070 - marketscreener.com
Barclays PLC (PEN) discloses 2.34M-share beneficial stake in Penumbra Inc - Stock Titan
Should Penumbra’s RED 68 Catheter Recall and Margin Strain Require Action From Penumbra (PEN) Investors? - webull.com
Penumbra, Inc. (PEN) stock price, news, quote and history - Yahoo Finance Singapore
Penumbra, Inc. (PEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Washington Trust Advisors, Inc.'s Penumbra Inc(PEN) Holding History - GuruFocus
THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care - Nonstop Local News Montana
Finanzdaten der Penumbra Inc-Aktie (PEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):